

Figure 4. Study of NSCLC proliferation and YAP1 localization after treatment with NXP900. **A.** IncuCyte images of LUAD and LUSC cells (masked in yellow) after treatment with DMSO (control) or NXP900 at different concentrations. Table displays NSCLC cell line characteristics (DepMap). **B.** Immunofluorescent confocal imaging study of YAP1 localization in A427 cells, NXP900 at 10 nM for 48-hours (x60). **C. Left:** Cell cycle analysis of A427 cells after treatment with 10 nM NXP900 for 48-hours. **Right:** Quantification of nuclear YAP1 in A427 cells after treatment with NXP900.

NXP900 demonstrates potent *in vivo* tumor growth inhibition in a YES1-amplified NSCLC model




Figure 5. *In vivo* efficacy study in YES1-gene amplified lung squamous cell carcinoma model: vehicle versus NXP900. Model: NSCLC YES1^{HIGH} – HCC95 (YES1 CNV=6, no other known driver mutations in addition to TP53 and CDKN2A, DepMap), Mouse Clinic for Cancer & Aging (MCCA) Intervention Unit of the Netherlands Cancer Institute, NKI-AVL. **A.** Analysis of tumor volume across 28 days. **B.** Analysis of mice body weights across the study.

Conclusions

- NXP900 prevents YAP1 nuclear localization and inhibits proliferation of NSCLC cell lines at low nM concentration.
- NXP900 potently inhibits tumor growth *in vivo* in a YES1-amplified lung squamous xenograft model.
- NXP900, currently in a Phase 1a dose escalation study, has single agent therapeutic potential in cancers displaying YES1 amplification and dysregulated Hippo signalling.

Acknowledgements and Contacts

With thanks to Nuvectis Pharma Inc. for a research grant to the University of Edinburgh
Boback Kaghzachi: bkaghzac@ed.ac.uk
Asier Unciti-Broceta, University of Edinburgh: asier.ub@ed.ac.uk
Neil Carragher, University of Edinburgh: n.carragher@ed.ac.uk
Enrique Poradosu, Nuvectis Pharma Inc.: eporadosu@nuvectis.com

References

1. C. C. Ayala-Aguilera, T. Valero, A. Lorente-Macias, D. J. Baillache, S. Croke, A. Unciti-Broceta, J Med Chem, 2022, 65, 1047-1131.
2. C. Temps, D. Lietha, E. R. Webb, X. F. Li, J. C. Dawson, M. Muir, K. G. Macleod, T. Valero, A. F. Munro, R. Contreras-Montoya, J. R. Luque-Ortega, C. Fraser, H. Beetham, C. Schoenherr, M. Lopalco, M. J. Arends, M. C. Frame, B. Z. Qian, V. G. Brunton, N. O. Carragher and A. Unciti-Broceta, Cancer Res, 2021, 81, 5438.
3. M. Higuchi, K. Ishiyama, M. Maruoka, R. Kanamori, A. Takaori-Kondo and N. Watanabe, Cell Rep, 2021, 34, 08876.